 NEW YORK, Nov. 17, 2020 GLOBE NEWSWIRE -- BeyondSpring Inc. the Company or BeyondSpring Nasdaq: BYSI, a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the launch of an underwritten public offering of 75 million of its ordinary shares. The Company also expects to grant the underwriters an option to purchase up to an additional 11.25 million of the ordinary shares being offered. The Company intends to use the net proceeds of this offering to support the commercialization of Plinabulin, continued clinical and pre-clinical development and for general corporate purposes. 